Protein engineering approaches for antibody fragments: directed evolution and rational design approaches.
Antibody
afinity
antibody fragment
biophysical properties
directed evolution
phage display
protein engineering
rational design
yeast surface display
Journal
Turkish journal of biology = Turk biyoloji dergisi
ISSN: 1303-6092
Titre abrégé: Turk J Biol
Pays: Turkey
ID NLM: 9434434
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
2
4
2019
pubmed:
2
4
2019
medline:
2
4
2019
Statut:
epublish
Résumé
The number of therapeutic antibodies in preclinical, clinical, or approved phases has been increasing exponentially, mostly due to their known successes. Development of antibody engineering methods has substantially hastened the development of therapeutic antibodies. A variety of protein engineering techniques can be applied to antibodies to improve their afinity and/or biophysical properties such as solubility and stability. Antibody fragments (where all or some parts of constant regions are eliminated while the essential antigen binding region is preserved) are more suitable for protein engineering techniques because there are many in vitro screening technologies available for antibody fragments but not full-length antibodies. Improvement of biophysical characteristics is important in the early development phase because most antibodies fail at the later stage of development and this leads to loss of resources and time. Here, we review directed evolution and rational design methods to improve antibody properties. Recent developments in rational design approaches and antibody display technologies, and especially phage display, which was recently awarded the 2018 Nobel Prize, are discussed to be used in antibody research and development.
Identifiants
pubmed: 30930630
doi: 10.3906/biy-1809-28
pmc: PMC6426644
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-12Déclaration de conflit d'intérêts
CONFLICT OF INTEREST: none declared
Références
Biochemistry. 1999 Jul 6;38(27):8739-50
pubmed: 10393549
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11211-6
pubmed: 10500156
J Mol Biol. 2001 Feb 2;305(5):989-1010
pubmed: 11162109
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D120-1
pubmed: 14681373
J Immunol Methods. 2004 Jul;290(1-2):69-80
pubmed: 15261572
Bioinformatics. 2004 Aug 4;20 Suppl 1:i63-8
pubmed: 15262782
J Mol Biol. 2004 Aug 27;341(5):1317-26
pubmed: 15302561
Nat Biotechnol. 2004 Oct;22(10):1302-6
pubmed: 15361882
J Mol Biol. 2005 Jul 8;350(2):379-92
pubmed: 15925383
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W306-10
pubmed: 15980478
Proteins. 2006 Mar 1;62(4):1125-32
pubmed: 16372356
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9637-42
pubmed: 16763048
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W239-42
pubmed: 16845001
Adv Drug Deliv Rev. 2006 Dec 30;58(15):1622-54
pubmed: 17123658
BMC Bioinformatics. 2007 Feb 27;8:65
pubmed: 17324296
Nat Protoc. 2006;1(2):755-68
pubmed: 17406305
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8247-52
pubmed: 17494738
Chem Soc Rev. 2008 Jul;37(7):1395-401
pubmed: 18568165
Methods Mol Biol. 2009;525:337-52, xiv
pubmed: 19252852
Appl Microbiol Biotechnol. 2010 Jan;85(4):909-19
pubmed: 19885657
MAbs. 2010 Jan-Feb;2(1):77-83
pubmed: 20093855
Pharm Res. 2010 Aug;27(8):1512-29
pubmed: 20422267
Neurologia. 2011 Jun;26(5):301-6
pubmed: 21193249
J Pharm Sci. 2011 Dec;100(12):5081-95
pubmed: 21789769
Bioinformatics. 2011 Dec 1;27(23):3286-92
pubmed: 21998155
Nat Biotechnol. 2012 Jan 09;30(1):69-77
pubmed: 22231104
Arch Biochem Biophys. 2012 Oct 15;526(2):87-98
pubmed: 22244834
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10879-84
pubmed: 22745168
Methods. 2012 Sep;58(1):40-6
pubmed: 22819858
PLoS One. 2012;7(10):e46084
pubmed: 23144695
Biologicals. 2013 Jul;41(4):209-16
pubmed: 23647952
MAbs. 2014 Jan-Feb;6(1):236-45
pubmed: 24256948
MAbs. 2014 Jan-Feb;6(1):73-85
pubmed: 24262785
BMC Bioinformatics. 2014 Feb 24;15:54
pubmed: 24564523
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W301-7
pubmed: 24848016
Int Immunol. 2014 Dec;26(12):649-57
pubmed: 25135889
Int Immunopharmacol. 2014 Dec;23(2):380-6
pubmed: 25281392
J Mol Biol. 2015 Jan 30;427(2):478-90
pubmed: 25451785
Bioinformatics. 2015 May 15;31(10):1698-700
pubmed: 25600945
Nature. 2015 Feb 5;518(7537):27-9
pubmed: 25652980
Protein Eng Des Sel. 2015 Mar;28(3):59-66
pubmed: 25655396
Mol Pharm. 2015 May 4;12(5):1443-55
pubmed: 25871775
Nucleic Acids Res. 2015 Jul 1;43(W1):W306-13
pubmed: 25883144
MAbs. 2016;8(1):99-112
pubmed: 26514585
J Biochem. 2016 May;159(5):519-26
pubmed: 26711234
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):45-62
pubmed: 26994592
Bioinformatics. 2016 Jul 1;32(13):2032-4
pubmed: 27153720
Adv Drug Deliv Rev. 2017 Feb;110-111:13-37
pubmed: 27210583
Nucleic Acids Res. 2016 Jul 8;44(W1):W469-73
pubmed: 27216816
Methods. 2016 Aug 15;106:3-13
pubmed: 27312879
Curr Opin Struct Biol. 2016 Jun;38:163-73
pubmed: 27525816
J Mol Biol. 2017 Feb 3;429(3):356-364
pubmed: 27561707
Adv Drug Deliv Rev. 2017 Dec 1;122:2-19
pubmed: 27916504
Microbiol Res. 2017 Mar;196:118-128
pubmed: 28164786
J Mol Biol. 2017 Apr 21;429(8):1244-1261
pubmed: 28322916
Nucleic Acids Res. 2017 Jul 3;45(W1):W236-W240
pubmed: 28505312
Nucleic Acids Res. 2017 Jul 3;45(W1):W229-W235
pubmed: 28525590
Bioinformatics. 2017 Oct 1;33(19):3098-3100
pubmed: 28575391
MAbs. 2017 Aug/Sep;9(6):996-1006
pubmed: 28613102
Sci Rep. 2017 Aug 15;7(1):8200
pubmed: 28811609
Transfus Med Hemother. 2017 Sep;44(5):312-318
pubmed: 29070976
Curr Opin Biotechnol. 2018 Jun;51:32-38
pubmed: 29175708
MAbs. 2018 Feb/Mar;10(2):183-203
pubmed: 29300693
Toxins (Basel). 2018 Jun 09;10(6):
pubmed: 29890762
Biol Pharm Bull. 2018;41(7):1062-1070
pubmed: 29962401
Adv Drug Deliv Rev. 2018 May;130:39-49
pubmed: 29964079
Science. 1985 Jun 14;228(4705):1315-7
pubmed: 4001944
Trends Biotechnol. 1993 Jan;11(1):6-10
pubmed: 7763382
Science. 1993 Dec 10;262(5140):1680-5
pubmed: 8259512
Proc Natl Acad Sci U S A. 1997 May 13;94(10):4937-42
pubmed: 9144168
Fold Des. 1998;3(1):R9-23
pubmed: 9502314